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OBJECTIVES: Older adult patients are underrepresented in
clinical trials comparing non–vitamin K antagonist oral
anticoagulants (NOACs) and warfarin. This subgroup anal-
ysis of the ARISTOPHANES study used multiple data
sources to compare the risk of stroke/systemic embolism
(SE) and major bleeding (MB) among very old patients with
nonvalvular atrial ﬁbrillation (NVAF) prescribed NOACs
or warfarin.
DESIGN: Retrospective observational study.
SETTING: The Centers for Medicare & Medicaid Services
and three US commercial claims databases.
PARTICIPANTS: A total of 88 582 very old (aged ≥80 y)
NVAF patients newly initiating apixaban, dabigatran,
rivaroxaban, or warfarin from January 1, 2013, to
September 30, 2015.
MEASUREMENTS: In each database, six 1:1 propensity
score matched (PSM) cohorts were created for each drug
comparison. Patient cohorts were pooled from all four data-
bases after PSM. Cox proportional hazards models were
used to estimate hazard ratios (HRs) of stroke/SE and MB.
RESULTS: The patients in the six matched cohorts had a
mean follow-up time of 7 to 9 months. Compared with
warfarin, apixaban (HR = .58; 95% conﬁdence interval
[CI] = .49-.69), dabigatran (HR = .77; 95% CI = .60-.99),
and rivaroxaban (HR = .74; 95% CI = .65-.85) were associ-
ated with lower risks of stroke/SE. For MB, apixaban
(HR = .60; 95% CI = .54-.67) was associated with a lower
risk; dabigatran (HR = .92; 95% CI = .78-1.07) was associ-
ated with a similar risk, and rivaroxaban (HR = 1.16; 95%
CI = 1.07-1.24) was associated with a higher risk compared
with warfarin. Apixaban was associated with a lower risk
of stroke/SE and MB compared with dabigatran (stroke/SE:
HR = .65; 95% CI = .47-.89; MB: HR = .60; 95% CI =
.49-.73) and rivaroxaban (stroke/SE: HR = .72; 95% CI =
.59-.86; MB: HR = .50; 95% CI = .45-.55). Dabigatran was
associated with a lower risk of MB (HR = .77; 95% CI =
.67-.90) compared with rivaroxaban.
CONCLUSION: Among very old NVAF patients, NOACs
were associated with lower rates of stroke/SE and varying
rates of MB compared with warfarin. J Am Geriatr Soc
00:1-10, 2019.
Key words: oral anticoagulants; atrial ﬁbrillation; stroke;
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The presence of atrial ﬁbrillation (AF) is an independentrisk factor for stroke, and the percentage of stroke
events that could be attributed to AF increases signiﬁcantly
with age.1 The stroke and major bleeding (MB) risk stratiﬁ-
cation schemas, CHA2DS2-VASc and HAS-BLED, consider
age as a risk factor for stroke/thromboembolism and MB,
respectively, in patients with AF.2,3
Clinical evidence favors treatment with oral anticoagu-
lants (OACs) to prevent stroke/systemic embolism (SE)
in very old adults given that the beneﬁts are considered to
outweigh the risk of MB.4,5 Randomized clinical trials
(RCTs) demonstrated that non–vitamin K antagonist oral
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anticoagulants (NOACs), including apixaban, dabigatran,
edoxaban, and rivaroxaban, have a lower frequency of
stroke/SE and a noninferior risk of MB compared with con-
ventional therapy, such as vitamin K antagonists (VKAs),
among patients aged 75 years and older.6-8
The 2018 European Heart Rhythm Association Practi-
cal Guide suggests that use of NOACs rather than VKA led
to a larger risk reduction among older patients9 due to the
higher risk for stroke/SE and MB in this population. A sys-
tematic review among AF patients (aged 65 y or older)
comparing NOACs with VKAs suggested that NOACs have
favorable results for hemorrhagic stroke and intracranial
hemorrhage (ICH).10 Using the Fit-for-the-Aged (FORTA)
classiﬁcation and Delphi process, warfarin, dabigatran,
edoxaban, and rivaroxaban were labeled B (beneﬁcial;
safely and effectively treat AF), and apixaban was labeled A
(absolutely; most beneﬁcial risk-beneﬁt ratio) for the treat-
ment of AF in patients aged 65 years or older.11
Although OACs are recommended for patients with AF
and a high CHA2DS2-VASc score, it was consistently
reported that less than 50% of patients aged 80 to 89 years
are treated with OACs, with reasons pertaining to safety
concerns rather than related to efﬁcacy, such as fear of
bleeding, perceived harm greater than beneﬁt, poor health,
and geriatric syndromes.12 Moreover, the ﬁnancial burden
and health plan restrictions related to the prescription of
NOACs might also serve as potential barriers to treatment.
More than 50% of the nonvalvular atrial ﬁbrillation
(NVAF) patients are 80 years or older, yet only one-third of
the patients enrolled in the four landmark NVAF trials of
the NOACs were 75 years of age or older.13 As the older
adult US population increases, this becomes an increasingly
important group to study.
This analysis of older patients (aged ≥80 y) in the
ARISTOPHANES (Anticoagulants for Reduction in Stroke:
Observational Pooled analysis on Health Outcomes and
Experience of Patients [NCT03087487]) study aimed to
provide complementary information for this underrepre-
sented population by evaluating and comparing the rates of
stroke/SE and MB among NVAF patients newly prescribed
apixaban, dabigatran, rivaroxaban, or warfarin.
METHODS
Data Sources
The details of the data description and pooling process of
the ARISTOPHANES study were published previously.14,15
In brief, data in this study were pooled from the US Centers
for Medicare & Medicaid Services (CMS) database and
three commercial claims databases in the United States: the
IMS PharMetrics Plus Database (“PharMetrics”), the
Optum Clinformatics Data Mart (“Optum”), and
the Humana Research Database (“Humana”). Collectively,
the four data sets cover more than 123 million beneﬁciaries
annually that account for approximately 38% of the US
population. The Truven MarketScan Commercial Claims
and Encounter database, used in the ARISTOPHANES
study, was not included in this subgroup analysis because
all patients are working-age adults who are younger than
65 years.15 Also, the MarketScan Medicare Supplemental
and Coordination of Beneﬁts Database (patients >65 y) was
not included in the ARISTOPHANES study to avoid poten-
tial duplicates of beneﬁciaries with both CMS Medicare
fee-for-service and Medicare supplementary insurance. In
addition, the analysis was conducted using CMS data indi-
vidually when examining outcomes or subgroups for which
other commercial data sets do not have comprehensive
information.
Patient Selection
This subgroup analysis of the ARISTOPHANES study
focused on very old (≥80 y) NVAF patients newly treated
with apixaban, dabigatran, rivaroxaban, or warfarin. AF
patients with an OAC pharmacy claim between January
1, 2013, and September 30, 2015 (identiﬁcation period)
were selected. The ﬁrst NOAC pharmacy claim during the
identiﬁcation period was designated as the index date for
patients with any NOAC claim(s). For those without a
NOAC claim, the ﬁrst warfarin prescription date was desig-
nated as the index date.16 The baseline period was deﬁned
as 12 months before or on the index date in an effort to
restrict the population to new initiators.
Patients were excluded if they were treated with an
OAC within 12 months before the index date, had evidence
of valvular heart disease, venous thromboembolism, tran-
sient AF (pericarditis, hyperthyroidism, thyrotoxicity), or
heart valve replacement/transplant during the baseline
period; were pregnant during the study period; or had hip
or knee replacement surgery within 6 weeks before the
index date. Detailed selection criteria can be found in
Figure 1.
Outcome Measures
Stroke/SE and MB were the primary outcomes. Stroke/SE
and MB were identiﬁed based on hospitalizations with
stroke/SE or MB as the principal (Medicare and Optum) or
ﬁrst listed (Humana and PharMetrics) diagnosis. Stroke/SE
was stratiﬁed by ischemic stroke, hemorrhagic stroke, and
SE; MB was stratiﬁed by gastrointestinal (GI) bleeding,
ICH, and MB at other key sites (Table S1).17,18 All-cause
mortality was evaluated using the CMS data, given that
only CMS data provide reliable validated death information
from the Social Security Administration.
The follow-up period was from the day after the index
date to the earliest of the following: 30 days after the dis-
continuation date, switch date, death (only inpatient death
for the commercial databases and all-cause death for the
Medicare database), end of continuous medical or phar-
macy plan enrollment, or the end of the study period
(September 30, 2015).
Statistical Methodology
Propensity score matching (PSM) was chosen for the com-
parative analysis of the effectiveness and safety proﬁles
among very old NVAF patients initiated on OACs. The
rationale of PSM and the detailed matching process can be
found in previous publications.14,15 Six PSM pairs were cre-
ated between NOACs and warfarin (apixaban vs warfarin,
dabigatran vs warfarin, and rivaroxaban vs warfarin) and
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between the NOACs (apixaban vs dabigatran, apixaban vs
rivaroxaban, and dabigatran vs rivaroxaban).
The propensity scores were generated using logistic
regressions with treatment cohorts and baseline characteris-
tics as covariates. The baseline covariates included demo-
graphics, Charlson Comorbidity Index score,19 bleeding
and stroke/SE history, comorbidities, and baseline co-
medications (complete list of covariates in Table S2). After
PSM, the balance of covariates was checked based on
standardized differences with a threshold of 10%.20
Patients in each arm of the comparison were pooled for
analysis after PSM in each data set. The P values <.05 were
considered statistically signiﬁcant.
Cox proportional hazard models with robust sandwich
estimates were used to evaluate the comparative risk of
stroke/SE and MB in each PSM cohort in the pooled popula-
tion, and all-cause mortality in each PSM cohort in the
Medicare population.21 Given that all the baseline covariates
Figure 1. Patient selection criteria. AF, atrial ﬁbrillation; ICD-9/10-CM, International Classiﬁcation of Diseases, Ninth/Tenth Revi-
sion, Clinical Modiﬁcation; OAC, oral anticoagulant; VTE, venous thromboembolism. *Edoxaban was not included in the study
given the recent Food and Drug Administration approval in 2015, and hence the small sample size (N = 14). [Late correction added
May 28, 2019, after ﬁrst online publication. Figure 1 legend was missing the footnote for *.]
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were balanced after matching, only OAC treatment was
included as an independent variable in the Cox models.
Subgroup and Sensitivity Analyses
In the ﬁrst subgroup analysis, the risk of stroke/SE and MB
were examined separately in standard dose NOAC
(apixaban 5 mg, dabigatran 150 mg, rivaroxaban 20 mg)
and lower dose NOAC (apixaban 2.5 mg, dabigatran
75 mg, rivaroxaban 15 mg/10 mg) patients based on the
index prescription dosage. PSM was reconducted in each
data set stratiﬁed by dose of NOACs before pooling. After
PSM and the pooling process, the same statistical methods
were used as the main analysis.
The second subgroup analysis was conducted to exam-
ine the risk of stroke/SE, MB, and all-cause mortality asso-
ciated with different age categories in the very old
population. Only CMS data provide comprehensive age
information that would allow this analysis, whereas com-
mercial data sets do not include speciﬁc age data beyond a
maximum age (eg, 84 y) due to privacy policies. Age strata
(80-84, 85-89, and ≥ 90 y) were created in the CMS post-
PSM population. In each age stratum, the post-PSM base-
line covariates with standardized differences more than
10% were included in the Cox proportional hazards model.
The statistical signiﬁcance of the interaction between age
and treatment was evaluated in the Cox models based on
P value with a threshold of .10.
Two sensitivity analyses were conducted to examine
the robustness of the comparative risk of stroke/SE and
MB. In the ﬁrst sensitivity analysis, Cox proportional haz-
ards models were separately conducted for CMS and the
pooled commercial data populations. In the second sensitiv-
ity analysis, all-cause mortality was included in the models
as a competing risk in the CMS population using the Fine
and Gray method.22
Because this study did not involve the collection, use,
or transmittal of individual identiﬁable data, institutional
review board approval was not required. Both the data sets
and the security of the ofﬁces where analysis was completed
(and where the data sets are kept) met the requirements of
the Health Insurance Portability and Accountability Act
of 1996.
RESULTS
After applying the selection criteria, a total of 103 511
NVAF patients 80 years or older were identiﬁed including
19 752 (19.1%) apixaban, 6741 (6.5%) dabigatran,
27 217 (26.3%) rivaroxaban, and 49 801 (48.1%) warfarin
patients (Figure 1). More than 80% of the patients had
CHA2DS2-VASc of 4 or higher, and more than 70% had
HAS-BLED of 3 or higher. For apixaban, dabigatran, and
rivaroxaban patients, 52% (2.5 mg), 37% (75 mg), and
51% (43% on 15 mg and 8% on 10 mg) had lower dosage
regimens, respectively (Table S2).
The unadjusted incidence rate of stroke/SE was 1.8
(apixaban), 2.2 (dabigatran), 2.2 (rivaroxaban), and 2.8
(warfarin) per 100 person-years. The unadjusted incidence
rate of MB was 4.9 (apixaban), 6.4 (dabigatran), 8.6
(rivaroxaban), and 7.4 (warfarin) per 100 person-years
(Table S2).
After PSM, 88 582 unique patients were included, with
18 897 apixaban-warfarin, 6698 dabigatran-warfarin,
25 917 rivaroxaban-warfarin, 6477 apixaban-dabigatran,
18 558 apixaban-rivaroxaban, and 6683 dabigatran-
rivaroxaban PSM pairs. The median follow-up time was
5 to 6 months for the matched cohorts. Select baseline char-
acteristics of the matched populations are shown in Tables 1
and 2 . The complete baseline characteristics can be found
in Tables S3 and S4.
The pre- and post-PSM baseline characteristics in the
very old CMS population meeting all eligibility criteria are
shown in Tables S5 to S7. The CMS patient population was
older, but other baseline characteristics generally had a sim-
ilar trend compared with the pooled population.
NOAC-Warfarin Comparisons
The Kaplan-Meier curves for cumulative incidence rates of
stroke/SE and MB in the matched populations are shown in
Figure S1A and S1B.
In the comparisons with warfarin, all NOACs were
associated with a lower risk of stroke/SE: apixaban (hazard
ratio [HR] = .58; 95% conﬁdence interval [CI] = .49-.69),
dabigatran (HR = .77; 95% CI = .60-.99), and rivaroxaban
(HR = .74; 95% CI = .65-.85). Ischemic stroke was the
most prevalent type of stroke/SE, of which the risk was
lower in apixaban and rivaroxaban patients compared with
warfarin patients. All NOACs were associated with a lower
risk of hemorrhagic stroke vs warfarin.
Apixaban (HR = .60; 95% CI = .54-.67) was associ-
ated with a lower risk of MB compared with warfarin.
Dabigatran (HR = .92; 95% CI = .78-1.07) was associated
with a similar risk, and rivaroxaban (HR = 1.16; 95% CI =
1.07-1.24) was associated with a higher risk of MB com-
pared with warfarin. GI bleeding was most prevalent, which
showed the same trend as the overall MB. All NOACs were
associated with a lower risk of ICH vs warfarin (Figure 2A).
NOAC-NOAC Comparisons
In the comparisons between NOACs, apixaban was associ-
ated with a lower risk of stroke/SE and MB compared with
dabigatran (stroke/SE: HR = .65; 95% CI = .47-.89; MB:
HR = .60; 95% CI = .49-.73) and rivaroxaban (stroke/SE:
HR = .72; 95% CI = .59-.86; MB: HR = .50; 95% CI =
.45-.55). Dabigatran was associated with a similar risk of
stroke/SE (HR = 1.11; 95% CI = .84-1.46), and lower risk
of MB (HR = .77; 95% CI = .67-.90) compared with
rivaroxaban (Figure 2B).
All-Cause Mortality
In the CMS population, compared with warfarin, all NOACs
were associated with a lower risk of all-cause mortality:
apixaban (HR = .61; 95% CI = .56-.67), dabigatran (HR =
.87; 95% CI = .75-.99), and rivaroxaban (HR = .87; 95%
CI = .81-.93). Apixaban was associated with a lower risk of all-
cause mortality compared with dabigatran (HR = .78; 95%
CI = .66-.91) and rivaroxaban (HR = .71; 95% CI = .64-.77).
Dabigatran was associated with a similar risk of all-cause mor-
tality (HR = .95; 95% CI = .82-1.09) compared with
rivaroxaban (Figure S2).
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Subgroup and Sensitivity Analyses
In the dose subgroup analysis among the pooled popula-
tion, the pre- and post-PSM baseline characteristics are
shown in Tables S8 to S13. After PSM, both lower and
standard dose patients showed broadly consistent results to
the main analysis (Figure S3).
In the age subgroup analysis among the CMS popula-
tion, the results for stroke/SE, MB, and all-cause mortality
were generally consistent with the main analysis. Several
signiﬁcant interactions were found for all-cause mortality.
For example, compared with warfarin, the risk of all-cause
mortality was lower for rivaroxaban patients aged 80 to
Figure 2. Propensity score matched incidence rates and hazard ratios of stroke/systemic embolism (SE) and major bleeding for A,
non–vitamin K antagonist oral anticoagulants (NOACs) vs warfarin and B, NOAC vs NOAC. CI, conﬁdence interval; GI, gastroin-
testinal; ICH, intracranial hemorrhage; SE, systemic embolism. [Late correction added May 22, 2019, after ﬁrst online publication.
Figure 2, Part A was replaced to correct a statistic related to NOAC incidence of major bleeding.]
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84 years but was similar for those older than 85 years
(Figure S4).
The two sensitivity analyses showed generally consis-
tent results as the main analysis that supported the robust-
ness of the ﬁndings for comparative risk of stroke/SE and
MB (Tables S14 and S15).
DISCUSSION
This comparative effectiveness and safety analysis among
patients aged 80 years or older in the ARISTOPHANES
study showed that very old NVAF patients who initiated
apixaban, dabigatran, or rivaroxaban were associated with
lower rates of stroke/SE compared with very old patients
who initiated warfarin, but the safety results varied across
NOACs. In the very old CMS Medicare population, all
NOACs were associated with a lower risk of all-cause mor-
tality compared with warfarin.
Very old subjects were underrepresented in the pivotal
phase III NOAC RCTs. Subgroup analyses by age in the
RCTs showed that older patients with NVAF who were
treated with OACs could have a distinct effectiveness and
safety proﬁle compared with younger patients.23-25 For
example, the analysis of the RE-LY trial showed a signiﬁ-
cant interaction between MB and age among NVAF
patients treated with dabigatran and warfarin: while
110 mg and 150 mg twice/day dabigatran were associated
with a lower risk of MB among patients younger than
75 years, they were associated with a similar risk in older
patients (≥75 y).23 The 110 mg and 150 mg twice/day
dabigatran were associated with a lower risk of stroke/SE
compared with warfarin for both young and older NVAF
patients.23 Similar trends were observed in our analysis of
patients aged 80 years or older; dabigatran was associated
with a similar risk of MB and lower risk of stroke/SE com-
pared with warfarin. In the ARISTOTLE and ROCKET AF
trials, no interactions between stroke/SE or MB and age
were found for patients younger than 75 years and older
(≥75 y) patients.24,25 In the ROCKET AF trial, 20 mg and
15 mg once/day rivaroxaban showed similar risk of
stroke/SE and MB compared with warfarin in both age
cohorts.24 In the ARISTOTLE trial, patients prescribed
apixaban had a lower risk of stroke/SE and MB in both
younger and older patients.25
In addition to RCTs, very few real-world studies have
been conducted to compare the safety and effectiveness
between OACs focusing on very old NVAF patients.13,26-28
Using different age categories and real-world data, these
studies provide supplementary information on the compara-
tive efﬁcacy and safety between NOACs and warfarin in
clinical practice. A population-based analysis on linked
claims data among patients aged 80 years or older in north-
eastern Italy found numerically lower risks of ischemic
stroke and MB among NOACs (dabigatran, rivaroxaban,
or apixaban) compared with warfarin users.26 Similarly, a
study among patients aged 90 years or older using the
National Health Insurance Research Database in Taiwan
found that NOACs were associated with a lower risk of
ICH with no difference in ischemic stroke.27 A retrospective
claims study using US MarketScan data comparing
rivaroxaban and warfarin found that, among NVAF
patients aged 80 years or older, rivaroxaban was associated
with a lower risk of stroke/SE and a similar risk of MB
compared with warfarin.13 This is also evident in a meta-
analysis including both real-world studies and RCTs, where
Bai et al concluded that among patients aged 65 years or
older, NOACs were associated with a decrease in risk of
MB and stroke/SE compared with warfarin.29
Several real-world studies were conducted with sub-
group analysis by age including age 80 years or older or
85 years, as subcategories.30-32 Consistent with previous
real-world studies, our study shows generally more favor-
able outcomes for NOACs vs warfarin in very old patients.
This study is by far the largest retrospective observa-
tional study examining the comparative effectiveness and
safety between OACs with the focus of very old NVAF
patients. In addition to the comparisons between NOACs
and warfarin, which would supplement the results of the
RCTs for each NOAC, comparisons between each NOAC
were also conducted. Moreover, the CMS Medicare data
were also used individually for the analysis of all-cause
mortality and the age subgroup analysis. By pooling four
data sets and including a comprehensive comparison of the
OACs, this study was able to add supplementary informa-
tion to the literature in assisting the decision of treatment
selection for stroke prevention among very old NVAF
patients.
Limitations
As with many real-world studies, our study has several limi-
tations. This study was designed to examine the associa-
tions between clinical outcomes and OAC treatment, so
causal relationships cannot be evaluated. As is the nature
with retrospective observational studies, our study was sub-
ject to confounders. Although PSM with a comprehensive
list of covariates was used, this study remains bound by the
limitation of claims data; variables such as over-the-counter
use of aspirin, serum creatinine/creatinine clearance, and
laboratory values are unavailable and thus were not con-
trolled for in the model. International Classiﬁcation of Dis-
eases, Ninth Revision, Clinical Modiﬁcation, codes were
used to identify baseline characteristics and outcomes that
may lack clinical accuracy. Moreover, age is top coded in
several data sets that may have caused the underestimation
of the mean age. Additionally, we are unable to determine
time in therapeutic range for patients prescribed warfarin.
The functional characteristics of patients are also unknown.
Nevertheless, by analyzing the real-world data, our study
reﬂects the quality of anticoagulation experienced by
patients in clinical practice. For example, given that very
old patients are likely to have a poorer measurement for the
international normalized ratio in real-world clinical prac-
tice, this may in part explain the higher risk of stroke/SE for
warfarin users in our study. Due to the lack of data on
renal function and body weight, it is not clear whether
patients used a lower dose of NOACs appropriately. In
addition, at the time of the study, no reversal agents were
available on the market for NOACs for patients with life-
threatening bleeding or requiring urgent surgery, which
may have impacted the choice of OAC treatment and the
safety results. Lastly, although the main and the additional
subgroup analyses added healthcare outcome evidence
related to the very old NVAF patient population who were
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newly prescribed OACs, limited generalizability of the
results to a different population, such as an institutionalized
older NVAF population, may be expected.
In conclusion, this retrospective observational study
among very old (≥80 y) NVAF patients newly initiated on
OACs showed that, compared with warfarin, NOACs were
associated with lower risks of stroke/SE and all-cause mor-
tality, and various comparative risks of MB. This study
adds to the growing body of evidence in a population that
is vulnerable and also at high risk of NVAF-related stroke.
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